Originally believed to be a manifestation of metabolic syndrome in the liver, NAFLD is now understood to contribute to the progression of atherosclerosis through various mechanisms, including the secretion of pro-inflammatory cytokines such as TNF-α and IL-6 (38). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.